Effect of trimetazidine for congestive heart failure: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 7, Issue 1, 2007, Pages 37-44

  Huang, Chang Quan ^a   Dong, Bi Rong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Congestive heart failure; Efficacy; Safety; Systematic review; Trimetazidine

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TRIMETAZIDINE;

ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; QUALITY OF LIFE; SYSTEMATIC REVIEW;

EID: 33846815035     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Mario M, Werner W. Efficacy and tolerability of trimetazidine in stable angina: ameta-analysis of randomized, double-blind, controlled trials. Coronary Artery Disease, 2003, 114 (2): 171-178.
2. Ciapponi A. Pizarro R,HarrisonJ. Trimetazidine for stable angina. nThe Cochrae Collaboration Volume (3), 2006.
3. Killalea S M, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. American Journal of Cardiovascular Drugs, 2001, 1(3): 193-204.
4. Jadad AR, Moore A, Carroll D, et al. Assessing the quality, of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
5. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention eficacy reported in Meta-analyses. Lancet, 1998, 352(9 128): 609-613.
6. Cristiana V, Mauricio W, Barbara S, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. European Heart Journal, 2004, 25: 1814-1821.
7. Gabrieleragasso F, Gianluca P, Francesco D, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosinetriph- osphate ratio in patients with heart failure. European Heart Journal, 2006, 27: 942-948
8. Di Napoli P, Taccardi A, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart, 2005, 91: 161-165.
9. Zhuang HP, Li J, Liu LH. Clinical observation of trimetazidine in the aged patients with chronic congestive Heart failure. Chinese Journal of Modern Mdeicine, 2003, 13(17): 124-1255.
10. Gabrieleragasso F, Altin, uccetti P, et al. A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure. Journal of the American College of Cardiology, 2006, 48(5): 992-998.
11. S Thrainsdottir, H Bibra, K Malmberg, et al. Effects of Trimetazidine on Left Ventricular Function in Patients with Type 2 Diabetes and Heart Failure. Cardiovasc Pharmaco, 2004, 7, 44(1): 101-108.
12. Bell D. Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care, 2003, 26: 2433-2441.
13. Dorn GD, Gerald W MD, Molkentin J, et al. Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men. Circulation, 2004, 109(2): 150-158.
14. Jiang MZ. The Effect of Trimetaj idine in Treatment of Heart Failure accompanied with Chronic Obstructire Pulmonary Disease.Practical Clinical Medicine (Jiangxi), 2005, 6(5): 11-12.
15. Fu SW, Jin Lie, Xu YH, et al. Study of Therapeutic Effect of Trimetazidine on Dilated Cardiomyopathy Accompanied by Congestive Heart Failur. Clinical Medical Journal of China, 2005, 12(3): 533-534.
16. Liu XB, Zhou DX, Ge JB. The effect of trimetazine on Cardiomyopathy Accompanied by Congestive Heart Failur. Jiangxi Medicine, 2005, 40(1): 50-51.